◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

Hydrochlorothiazide (HCTZ)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

HCTZ is a first-line antihypertensive — useful for documented hypertension, mild heart failure, kidney stones. Dylan has no hypertension, no heart failure, normal renal function. Bodybuilding "cutting" use carries severe electrolyte risks. Would change only if Dylan develops sustained HTN (unlikely at 20).

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    No HTN. Hyponatremia would crash cognition. WADA-prohibited (S5).

  • 30-50, executive maintenance
    RELEVANT IF HTN

    first-line option (or chlorthalidone for longer T1/2). Otherwise NOT-RELEVANT.

  • 50+, mild cognitive decline
    RELEVANT

    IF HTN as part of dementia prevention via BP control. Watch hyponatremia risk in elderly — many switch to chlorthalidone or amlodipine.

  • Anxiety-prone
    NOT-RELEVANT

    for nootropic reasons. If HTN exists, cardio-selective beta blocker may be more anxiety-friendly.

  • High athletic load, tested status
    SKIP

    (WADA prohibited as masking agent + diuretic, S5). Tested athletes face automatic bans.

  • Sleep-disordered
    NOT-RELEVANT

    directly, but evening dosing can cause nocturia → fragmented sleep. If used, take AM.

  • Recovery-focused
    NOT-RELEVANT
  • Strength/anabolic-focused
    SKIP

    for cutting use. Documented competition deaths. Even non-tested federations have lost competitors. Use diet/sodium manipulation instead. If competing, do so under medical supervision with K+ monitoring — not a DIY tool.

▸ Subjective experience (deep)
  • Within hours: increased urination, mild thirst, mild lightheadedness on standing
  • Days 1-3: continued diuresis, possible muscle cramps if K+/Mg drop
  • Chronic use: usually well-tolerated at 12.5-25 mg in HTN management
  • High-dose / cutting use (50-100 mg+): pronounced thirst, dizziness, weakness, cramps, palpitations, potential syncope
▸ Tolerance + cycling deep dive
  • No pharmacologic tolerance (effective for years in HTN)
  • Diuretic effect partially attenuates over weeks (compensated by RAAS), but BP effect persists
▸ Stacking deep dive

Synergistic with

  • Medical: ACEi/ARB combos (lisinopril/HCTZ, valsartan/HCTZ, telmisartan/HCTZ) — synergistic BP lowering with K+ neutralization
  • Medical: Loop diuretic in resistant edema (sequential nephron blockade)

Avoid stacking with

  • Lithium (HCTZ ↑ lithium reabsorption → toxicity)
  • Other K+-wasting drugs (loop diuretics, corticosteroids, amphotericin) without supplementation
  • Bodybuilding: Other diuretics (furosemide stacked with thiazide for "synergy") — has killed competitors
  • Beta-2 agonists (clenbuterol stack — additive K+ loss)
  • NSAIDs chronically (blunts BP effect, raises kidney injury risk)

Neutral / safe co-administration

  • Most non-cardiac biohacker compounds are neutral if HCTZ is medically indicated
▸ Drug interactions deep dive
  • ↑ lithium toxicity (significant)
  • ↑ digoxin toxicity (via hypokalemia)
  • ↓ effect of antidiabetic drugs (mild hyperglycemia)
  • NSAIDs blunt BP-lowering effect
  • Cholestyramine reduces absorption
▸ Pharmacogenomics
  • SLC12A3 polymorphisms exist but not clinically actionable for HCTZ dosing
  • HLA-related cutaneous reaction risk not as well-characterized as for some other drugs
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Generic Rx (US) Any pharmacy $4-10/month at 25 mg high Standard generic
Combo products Various (with lisinopril, losartan, etc.) varies high Standard antihypertensive
Bodybuilding gray-market Various varies low Black-market diuretic stacks (often combined with K+ supplements that don't fully compensate)

For Dylan: Don't source.

▸ Biomarkers to track (deep)
  • Baseline (if starting medically): BMP (Na, K, Cl, HCO3, BUN, Cr, glucose), Mg, uric acid, lipid panel
  • During use: BMP at 1-2 weeks then quarterly; Mg as needed; annual BMP and lipids
  • Post-cycle: N/A — chronic medical use
▸ Controversies / open debates Live debate
  • HCTZ vs chlorthalidone: Chlorthalidone has longer half-life (40-60h vs 6-15h), more 24h BP coverage, more outcome data. Many cardiology groups prefer it. HCTZ persists due to formulary inertia and combo-product convenience.
  • Skin cancer signal: Pedersen 2018 + Danish series triggered EMA/FDA label updates. Real but in absolute terms small for short-term use; consequential for decades-long chronic exposure.
  • Bodybuilding cutting practice persists despite documented deaths (Mohammed Benaziza 1992 widely attributed to diuretic-induced K+/electrolyte collapse; multiple subsequent cases). Practice continues because pre-show "dry" look is competition-rewarded.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT HIGH. Filed alongside novolin-r, BMP-2, OGP as part of Dylan's "user-dump completeness" wave. No clinical or biohacker use case for him.
▸ Open questions / gaps Open
  • Whether SCC risk is materially different for chlorthalidone (similar mechanism, similar photosensitization expected) — emerging.
  • Whether SGLT2 inhibitors will displace thiazides in HTN management (not yet, but watch).
▸ Sources (full, with our context)
Back to compact view